FDA advisory panel votes to place popular peptide TB-500 on compounding list | Reuters

An FDA advisory panel voted 8-6 to place TB-500, a popular peptide, on the pharmacy compounding list, allowing broader production outside traditional pharmaceutical manufacturing. The FDA is not bound by the recommendation and will make the final decision.

This Wire brief sits within Fusion42's coverage of Digital Health. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.